These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Plasma factor Xa inhibition can predict antithrombotic effects of oral direct factor Xa inhibitors in rabbit atherothrombosis models. Funatsu T; Yamashita A; Kaku S; Iwatsuki Y; Asada Y Thromb Haemost; 2012 Nov; 108(5):896-902. PubMed ID: 23052641 [TBL] [Abstract][Full Text] [Related]
10. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Lu G; DeGuzman FR; Hollenbach SJ; Karbarz MJ; Abe K; Lee G; Luan P; Hutchaleelaha A; Inagaki M; Conley PB; Phillips DR; Sinha U Nat Med; 2013 Apr; 19(4):446-51. PubMed ID: 23455714 [TBL] [Abstract][Full Text] [Related]
11. The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure. Flierl U; Fraccarollo D; Micka J; Bauersachs J; Schäfer A Pharmacol Res; 2013 Aug; 74():49-55. PubMed ID: 23714416 [TBL] [Abstract][Full Text] [Related]
12. Alterations in fatty acid metabolism and sirtuin signaling characterize early type-2 diabetic hearts of fructose-fed rats. Lou PH; Lucchinetti E; Scott KY; Huang Y; Gandhi M; Hersberger M; Clanachan AS; Lemieux H; Zaugg M Physiol Rep; 2017 Aug; 5(16):. PubMed ID: 28830979 [TBL] [Abstract][Full Text] [Related]
13. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values. Siddiqui F; Tafur A; Ramacciotti LS; Jeske W; Hoppensteadt D; Ramacciotti E; Iqbal O; Fareed J Clin Appl Thromb Hemost; 2019; 25():1076029619863493. PubMed ID: 31298056 [TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Laux V; Perzborn E; Kubitza D; Misselwitz F Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849 [TBL] [Abstract][Full Text] [Related]
15. A role for coagulation factor Xa in experimental pulmonary arterial hypertension. Delbeck M; Nickel KF; Perzborn E; Ellinghaus P; Strassburger J; Kast R; Laux V; Schäfer S; Schermuly RT; von Degenfeld G Cardiovasc Res; 2011 Oct; 92(1):159-68. PubMed ID: 21676958 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes. Gopalakrishnan L; Kumar V; Kohli P; Singh P; Rastogi U; Gibson CM Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):889-900. PubMed ID: 22577900 [TBL] [Abstract][Full Text] [Related]
18. Effect of the factor Xa inhibitor rivaroxaban on arterial thrombosis in wild-type and apolipoprotein E-deficient mice. Wagner NM; Dressel T; Schäfer K; Konstantinides S Thromb Res; 2012 Nov; 130(5):793-8. PubMed ID: 22281071 [TBL] [Abstract][Full Text] [Related]
19. Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue. Bukowska A; Zacharias I; Weinert S; Skopp K; Hartmann C; Huth C; Goette A Eur J Pharmacol; 2013 Oct; 718(1-3):114-23. PubMed ID: 24041930 [TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. Perzborn E; Kubitza D; Misselwitz F Hamostaseologie; 2007 Sep; 27(4):282-9. PubMed ID: 17938768 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]